Columbia University Minority/Underserved Site NCI Community Oncology Research Program
Columbia University Minority/Underserved Site NCI Community Oncology Research Program
批准号:
10673181
负责人:
Jennifer E. Amengual
金额:
$102.1万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-08-01 至 2025-07-31
关键词:
Advisory CommitteesAgeCancer BurdenCancer CenterCancer ControlCancer PatientCatchment AreaClinical ResearchClinical TrialsClinical Trials NetworkCollaborationsCommunitiesCommunity Clinical Oncology ProgramCommunity HealthContinuity of Patient CareEnrollmentEthnic OriginGenderGoalsHealth PersonnelHerbert Irving Comprehensive Cancer CenterIndividualInfrastructureInstitutional Review BoardsLeadLeadershipMedical centerMinorityMinority GroupsMinority ParticipationPatientsPhasePopulationPreventionQuality of lifeRaceResearchRoleSex OrientationSiteSocioeconomic StatusTherapeutic TrialsTissuesUniversitiesbasebiobankcancer carecancer clinical trialcancer preventioncancer therapycare deliverydesignhealth care disparityimprovednovel therapeuticsoutreachpatient populationprogramsscreeningunderserved community
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The Herbert Irving Comprehensive Cancer Center’s Minority/Underserved National Community Oncology
Research Program at Columbia University Irving Medical Center (HICCC/CUIMC/MU-NCORP) has established
a robust infrastructure that facilitates the identification, activation and participation in NCORP Research Base
clinical trials. The overall goal of the HICCC/CUIMC/MU-NCORP is to provide the best in cancer care to the
minority/undeserved population that surrounds our cancer center. The specific aims of our program are to 1)
Provide and enhance access for our community of patients and healthcare providers to a portfolio of NCI Clinical
Trials Network (NCTN/NCORP) trials, specifically in the four components of cancer control, cancer prevention
and screening, cancer care delivery (CCD) research and cancer treatment (Phase I, II, III) as well as tissue
acquisition; 2) Enhance the accrual of minority and underserved patients onto these trials by promoting the
accessibility and availability of the trial portfolio and identifying and reducing accrual barriers to meet the needs
of our community, 3) Lead, participate, and promote NCORP/NCTN research base studies across the cancer
care continuum with a particular focus on studies that reduce healthcare disparities, and 4) Collaborate and
contribute to the NCI NCORP-wide activities. Over the past four years, this strong infrastructure has led to many
accomplishments. Our MU-NCORP portfolio consists of over 150 trials, and we have enrolled over 500 patients
to Cancer Control and Prevention, Cancer Care Delivery and Therapeutic Trials. We have consistently exceeded
the minimum 30% accrual target for minority and underserved patient populations. In addition, we have taken
leadership roles within the research bases and lead many trials. By facilitating the enrollment and participation of
minority and underserved cancer patients into high impactful clinical trials, we will achieve our ultimate goal of
improving survival and quality of life of all individuals regardless of age, race, ethnicity, gender, sexual orientation
or socioeconomic status.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
-
批准号:10470919
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2018
-
负责人:Jennifer E. Amengual
-
依托单位:
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
-
批准号:10241324
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2018
-
负责人:Jennifer E. Amengual
-
依托单位:
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
-
批准号:9790953
-
项目类别:
-
资助金额:$35.95万
-
财政年份:2018
-
负责人:Jennifer E. Amengual
-
依托单位:
Columbia University Minority/Underserved Site NCI Community Oncology Research Program
-
批准号:10456730
-
项目类别:
-
资助金额:$101.61万
-
财政年份:2014
-
负责人:Jennifer E. Amengual
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: